PMID-27138887 – Brain-gut Axis and Pentadecapeptide BPC 157
Sikiric P et al. "Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications," Current Neuropharmacology, 2016;14(8):857-865. doi:10.2174/1570159×13666160502153022
Quick Reference
| Property | Value |
|---|---|
| PMID | 27138887 |
| DOI | 10.2174/1570159×13666160502153022 |
| Year | 2016 |
| Journal | Current Neuropharmacology |
| Study Type | Narrative Review |
| Evidence Level | V |
| Sample | Review of preclinical studies on BPC 157 and brain-gut axis |
| Peptide(s) Studied | BPC-157 |
Key Findings
- BPC 157 modulates the brain-gut axis bidirectionally: peripheral administration produces central effects and vice versa
- Documented neuroprotective effects including somatosensory neuron protection, peripheral nerve regeneration, and recovery after traumatic brain injury (TBI)
- BPC 157 modulates both serotonergic and dopaminergic neurotransmitter systems
- No toxic effects observed at any dose level tested across multiple preclinical models
- Counteracts dopamine system perturbations (both overactivity and deficiency models)
- GI protective effects extend to CNS-mediated conditions including anxiety-like and depression-like behaviors in animal models
Study Design
Narrative review synthesizing the Sikiric group's preclinical evidence on BPC 157's interactions with the brain-gut axis. Covers neuroprotection, neurotransmitter modulation, and bidirectional signaling between GI tract and CNS.
Limitations
- Entirely preclinical evidence; no human neurological data
- Single-group evidence: nearly all studies reviewed are from the Sikiric laboratory
- Published in a neuropharmacology journal but evidence base is primarily animal behavioral studies
- Mechanism of action at the molecular level remains incompletely characterized
Clinical Relevance
Provides theoretical foundation for BPC 157's potential neurological applications beyond GI healing. The brain-gut axis framework is increasingly recognized in mainstream medicine. Relevant for practitioners exploring BPC-157 for conditions with GI-neurological overlap (e.g., IBS with anxiety, post-concussion syndrome). All clinical applications remain speculative without human trial data.
Related
#research #narrative-review #evidence-level-V